Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children
Asia Pacific Allergy
;
(4): e7-2019.
Article
Dans Anglais
| WPRIM
| ID: wpr-750167
ABSTRACT
Childhood asthma is one condition within a family of allergic diseases, which includes allergic rhinitis, atopic dermatitis, and food allergy, among others. Omalizumab is an anti-IgE antibody therapy that was approved in Japan for children with asthma and added to the Japanese pediatric asthma guidelines in 2017. This review highlights the Japanese clinical perspectives in pediatric allergic asthma, and consideration for allergic comorbidities, and reflects on omalizumab clinical trials in progress to present comprehensive future opportunities.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Asthme
/
Comorbidité
/
Asiatiques
/
Eczéma atopique
/
Rhinite allergique
/
Omalizumab
/
Hypersensibilité alimentaire
/
Japon
Type d'étude:
Guide de pratique
Limites du sujet:
Enfant
/
Humains
Pays comme sujet:
Asie
langue:
Anglais
Texte intégral:
Asia Pacific Allergy
Année:
2019
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS